NanoStar Pharmaceuticals

NanoStar Pharmaceuticals is a biotechnology company that specializes in advanced drug delivery technologies. The company designs and optimizes proprietary platforms, including liposomes and lipid nanoparticles (LNP), to overcome critical challenges in drug development such as poor solubility, low permeability, and poor stability. By utilizing sophisticated engineering and materials science, NanoStar creates innovative formulations for small molecules, proteins, and nucleic acids, enabling targeted delivery to specific cells and tissues. Their research and development efforts are supported by a multidisciplinary team with expertise in pharmacology, bioinformatics, and AI, aimed at developing next-generation therapeutics for diseases with limited treatment options.

As a preclinical contract research organization (CRO), NanoStar provides comprehensive development solutions to partners and clients, helping them accelerate therapeutic candidates from early-stage formulation to preclinical validation. Their services encompass formulation development, characterization, scale-up, and a suite of cell-based, in vitro, and animal studies to assess safety, efficacy, and pharmacokinetics. By addressing unmet formulation needs and providing customized preclinical support, the company enables the transformation of drugs with significant delivery hurdles into safe and effective treatments, with a particular focus on pediatric formulations, cancer immunotherapy, gene therapy, and transdermal delivery applications.